LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma

The use of LAG-3 expression as a clinical biomarker to select for patients who might benefit from anti-LAG-3 immuniotherapies might require multiple rapid, sensitive, and accurate assays. In this study, LAG-3 status by RNA-seq and immunohistochemistry (IHC) in melanoma were significantly correlated, but further research is required to establish RNA-seq cutoffs in larger and more diverse patient cohorts.